Yes, it is safe to get the flu shot now—in fact, it should be given as soon as possible.
Patients with recent coronary stents should receive the inactivated influenza vaccine without delay, as the vaccine does not interfere with antiplatelet therapy, does not increase bleeding risk, and provides critical cardiovascular protection during a high-risk period.
Why Vaccination is Safe and Beneficial Now
The inactivated influenza vaccine is not a surgical procedure and does not require interruption of dual antiplatelet therapy (aspirin plus clopidogrel/ticlopidine). The ACC/AHA guidelines specifically address timing concerns for noncardiac surgery after stent placement—recommending delays of 4-6 weeks for bare-metal stents and up to 12 months for drug-eluting stents to allow endothelialization 1. However, influenza vaccination is fundamentally different: it involves an intramuscular injection with no significant bleeding risk and no need to stop antiplatelet medications.
Strong Evidence for Early Post-ACS Vaccination
Multiple high-quality studies demonstrate that influenza vaccination given early after acute coronary syndrome (including post-stent placement) significantly reduces cardiovascular events:
The IAMI trial (2023), the most recent large randomized study, enrolled 2,571 patients and administered in-hospital influenza vaccination after MI with excellent results. The vaccine reduced the composite endpoint of death, MI, or stent thrombosis at 12 months, with particularly strong benefits in NSTEMI patients (HR 0.60,95% CI 0.39-0.91) 2.
The FLUVACS trial randomized 301 patients hospitalized for MI or planned angioplasty/stenting to receive influenza vaccination versus no vaccination. At 1 year, cardiovascular mortality was dramatically reduced (2% vs 8%, relative risk 0.25) 3.
A 2011 randomized trial of 439 ACS patients showed major cardiovascular events occurred less frequently in the vaccine group (9.5% vs 19.3%, HR 0.70) 4.
Official Guideline Recommendations
The AHA/ACC 2006 guidelines explicitly recommend influenza vaccination for patients with cardiovascular disease as Class I, Level B secondary prevention—the same strength of recommendation as aspirin, statins, and beta-blockers 5, 6. The guidelines emphasize that:
- Patients with CVD should receive annual influenza vaccination 5
- The inactivated vaccine is safe and does not cause influenza illness 6
- No evidence suggests influenza vaccination is harmful for individuals with cardiovascular conditions 6
- Vaccination can be given throughout the influenza season, not just in fall 6
Key Safety Points
- Continue all antiplatelet medications: There is no need to stop aspirin or clopidogrel for the flu shot 1
- No increased bleeding risk: A large UK study of 39,000 CVD patients found no increased risk of MI or stroke in the 90 days after influenza vaccination 6
- Use inactivated vaccine only: The live attenuated nasal vaccine is contraindicated in CVD patients, but the intramuscular inactivated vaccine is safe 6
Contraindications to Check
Only delay vaccination if the patient has:
- Known anaphylactic hypersensitivity to eggs
- History of Guillain-Barré syndrome (requires physician consultation)
- Moderate-to-severe acute febrile illness (wait until symptoms resolve) 6
Bottom Line
Give the flu shot now. Three days post-stent is an ideal time for vaccination—the patient is still under close medical supervision, cardiovascular risk remains elevated, and early vaccination provides protection during the critical post-ACS period when influenza infection could trigger catastrophic events. The evidence shows that early post-MI/post-stent vaccination reduces mortality and cardiovascular events, with no safety concerns related to timing or antiplatelet therapy.